F
Fuchun Guo
Researcher at Sichuan University
Publications - 31
Citations - 711
Fuchun Guo is an academic researcher from Sichuan University. The author has contributed to research in topics: Cancer & Tumor microenvironment. The author has an hindex of 14, co-authored 27 publications receiving 554 citations.
Papers
More filters
Journal ArticleDOI
Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice.
Huashan Shi,Dan Li,Jing Zhang,Yongsheng Wang,Li Yang,Hailong Zhang,Xianhuo Wang,Bo Mu,Wei Wang,Yu Ma,Fuchun Guo,Yuquan Wei +11 more
TL;DR: The effects of combining shRNA targeting PKM2 and docetaxel on human A549 lung carcinoma cells both in vivo and in vitro suggest that targeting tumor glycolysis can increase the efficacy of chemotherapy.
Journal ArticleDOI
Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency
Wei Wang,Yu Ma,Jiyao Li,Huashan Shi,Li Wang,Fuchun Guo,Jie Zhang,Dan Li,Mo Bh,Fuqiang Wen,Ting Liu,Yantong Liu,Ye Wang,Yu Quan Wei +13 more
TL;DR: This study provides the rationale for the clinical translation of CAR-modified T lymphocytes with VEGFR-1 specificity by electroporation and demonstrated the antitumor and anti-angiogenesis ability of V-1 CAR- modified T lymphocyte.
Journal ArticleDOI
Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation
Sisi He,Tao Yin,Dan Li,Xiang Gao,Yang Wan,Xuelei Ma,Tinghong Ye,Fuchun Guo,Jianhong Sun,Ziqiang Lin,Yongsheng Wang +10 more
TL;DR: Gefitinib greatly enhanced NK cell cytotoxicity to lung cancer cells with EGFR L858R + T790M resistance mutation and combination of EGFR tyrokinase inhibitors and NK cells adoptive immunotherapy may represent a potentially effective strategy for patients with non-small cell lung cancer.
Journal ArticleDOI
Dopamine receptor antagonist thioridazine inhibits tumor growth in a murine breast cancer model
TL;DR: ThIORidazine was found to significantly inhibit breast tumor growth and the potential for thioridazine to be used in cancer therapy may be re-evaluated and investigated in clinical settings.
Journal ArticleDOI
Corrigendum: A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts.
Meihua Chen,Rong Xiang,Yuan Wen,Guang-chao Xu,Chun-Ting Wang,Shun-Tao Luo,Tao Yin,Xiawei Wei,Bin Shao,Ning Liu,Fuchun Guo,Meng Li,Shuang Zhang,Minmin Li,Kexing Ren,Yongsheng Wang,Yuquan Wei +16 more
TL;DR: It is indicated that the FAP-modified whole-cell tumor vaccine induced strong antitumor immunity against both tumor cells and CAFs and reversed the immunosuppressive effects of tumors by decreasing the recruitment of immunOSuppressive cells and enhancing the recruitmentof effector T cells.